Lead Product(s) : Apricoxib,Stimulon
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Agenus
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the collaboration with Targovax, Agenus will supply QS-21 STIMULON and scientific support for up to three initial TG01 clinical trials in different cancer indications.
Brand Name : TG01
Molecule Type : Vaccine
Upfront Cash : Undisclosed
March 07, 2022
Lead Product(s) : Apricoxib,Stimulon
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Agenus
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Apricoxib,Gemcitabine
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Innovation Norway
Deal Size : $0.9 million
Deal Type : Funding
Innovation Norway Awards NOK 8.2 mn Grant to Targovax for Development of TG Mutant RAS Vaccine
Details : With the support from Innovation Norway, Targovax has move the TG program forward faster and more broadly, and thus bring benefit to a patient group with poor prognosis and few available treatment options.
Brand Name : TG01
Molecule Type : Vaccine
Upfront Cash : Undisclosed
January 12, 2022
Lead Product(s) : Apricoxib,Gemcitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Innovation Norway
Deal Size : $0.9 million
Deal Type : Funding
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : IOVaxis Therapeutics
Deal Size : $3.0 million
Deal Type : Licensing Agreement
Details : Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore...
Brand Name : TG01
Molecule Type : Vaccine
Upfront Cash : Undisclosed
January 06, 2021
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : IOVaxis Therapeutics
Deal Size : $3.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : IOVaxis Therapeutics
Deal Size : $100.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, IOVaxis and Targovax will jointly define a development plan in the territory, and IOVaxis will be responsible for all local regulatory filings and will sponsor clinical trials.
Brand Name : TG01
Molecule Type : Vaccine
Upfront Cash : Undisclosed
January 08, 2020
Lead Product(s) : Apricoxib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : IOVaxis Therapeutics
Deal Size : $100.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?